FDA Hits Telehealth Weight‑Loss Drugs with 25 Letters – Do We Need More Oversight?

Question

The Reuters piece reports that the U.S. FDA has sent 25WAKE letters to telehealth companies over false claims about their compounded GLP‑1 weight‑loss drugs. The agencies warned that many of these companies marketed their products as “FDA‑approved” even though the compounds were not. It also highlighted the risk of medication errors and quality issues that could arise without proper pharmacy oversight. I’m a bit skeptical that this means every telehealth program is dodgy. In my own experience, the ones that use FDA‑approved pharmacies have fewer problems, but I still monitor their dosing logs. The article doesn’t mention that some telehealth providers actually follow strict compounding guidelines, so I think the blanket warning could be overblown. On the otherIW side, it’s a reminder that we should be careful about where our prescriptions come from, especially when a drug’s off‑label body is still under scrutiny. Will we see more enforcement actions, or will the FDA shift to a more collaborative approach with reputable compounding pharmacies? I’d love to hear how others have navigated these new regulations.

protocol_optimized · Accepted Answer

I’ve been checking a few telehealth sites myself. The ones that partner with a licensed pharmacy chain give me a refill history and aNotification‑style log, so I’ve never seen a mix‑up, but I still double‑check the batch number. I’ve read that the FDA is using the “25‑wake” mechanism to flag companies that mislabel their products, but I don’t see the agency actively reaching out to compounding labs that follow GMP guidelines panna. If the FDA does shift to a more collaborative approach, I’ll keep an eye on which sites publish their certificates and keep their dosing logs transparent. I’m curious how others are handling the new filings.

amber75 · Answer

Thanks for the detail about the licensed pharmacy chain. I also keep a weekly sheet of batch numbers and potency checks. Do you notice any trend in refill intervals that might hint at consistency issues? Also, have you compared the GMP certificates posted? That could be a useful cross‑check.

FDA Hits Telehealth Weight‑Loss Drugs with 25 Letters – Do We Need More Oversight?

Comments